查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
最小残留疾病检测市场规模,份额和趋势分析报告：按技术（NGS,PCR）,癌症类型（血液系统恶性肿瘤）,最终用途（医院）,地区,细分市场预测2023-2030
市场调查报告书
商品编码
1178627

最小残留疾病检测市场规模,份额和趋势分析报告：按技术（NGS,PCR）,癌症类型（血液系统恶性肿瘤）,最终用途（医院）,地区,细分市场预测2023-2030

Minimal Residual Disease Testing Market Size, Share & Trends Analysis Report By Technology (NGS, PCR), Cancer Type (Hematological Malignancy), By End-use (Hospitals), By Region, And Segment Forecasts, 2023 - 2030
出版日期: | 出版商: Grand View Research | 英文 130 Pages | 商品交期: 2-10个工作天内

价格

最小残留病检测市场增长和趋势

根据 Grand View Research, Inc. 的最新报告，到 2030 年，全球微小残留病检测市场预计将达到 45 亿美元，2023 年至 2030 年的复合年增长率为 11.45%。采用 MRD 测试作为一种新的诊断和预后测定已经产生了用于治疗所有类型的血液恶性肿瘤的紧密定制的治疗方案。 结果测量对于成功采用给定的癌症治疗方案至关重要。

MRD 产生重要的分子信息，以更好地了解癌症状态并最终利用治疗结果。 因此，MRD 测试越来越多地用作基于肿瘤学研究的众多临床试验研究中的终点分析步骤，并且还有效地记录了由于个体遗传特征而导致的治疗结果的变化。。 例如，2020 年 11 月，Adaptive Biotechnologies Corporation 与 GlaxoSmithKline plc. 展开合作，使用他们的 clonoSEQ 分析来评估 GSK 血液疗法治疗后残留的癌细胞。

手术切除肿瘤与其他治疗相结合併不能完全去除癌细胞。 癌症的痕迹可能会留在身体的某些部位或血液中。 诊断这些残留细胞对于确定未来是否需要化疗或放疗非常重要。 研究人员正在设计非侵入性测试以有效检测 MRD。 例如，2022 年 2 月，C2i Genomics 血液测试对肿瘤手术治疗后残留的癌细胞进行了量化。 C2inform 测试还具有 CE 标誌许可，并在欧洲作为“软件即医疗设备”MRD 测试提供。

肿瘤药物根据临床证据进行有效调节以防止肿瘤细胞持续存在，并根据个体的特定进展情况进行个体化。 许多研究增加了考虑个体遗传特征以进行有效治疗的必要性。 例如，2022 年 10 月，Adaptive Biotechnologies Corporation 与 Epic 合作，以增加对血癌 MRD 监测的访问。 此外，2021 年 2 月，Natera Inc. 与 Personalis Inc. 合作，为 NeXT 肿瘤分析（Personalis）和个性化 ctDNA 平台 Signatera 诊断产品（Natera, Inc.）有效设计治疗监测制度和 MRD 评估，以了解结果通过整合实现个性化的癌症护理。

微小残留病检测市场报告要点

MRD检测的高灵敏度和广泛适用性使流式细胞仪在2022年主导微小残留病检测市场

由于血液系统恶性肿瘤的患病率不断增加，预计血液系统恶性肿瘤部分在预测期内将以最快的速度增长

由于医院和专科诊所拥有先进的诊断设备和熟练的专业人员，医院和专科诊所部门将成为 2022 年收入最高的部门

由于该地区血液系统恶性肿瘤的患病率上升以及报销环境的改善，北美将在 2022 年主导微小残留病检测市场

>

内容

第一章调查方法及范围

  • 市场细分
  • 调查方法
  • 信息采购
    • 购买的数据库
    • 次要信息
    • 初步调查
    • 初步调查的详细信息
  • 信息或数据分析
    • 数据分析模型
  • 市场製定和验证
  • 模型详细信息
    • 商品流分析
      • 方法 1：商品流方法
      • 方法 2：使用自下而上的方法逐个国家/地区进行市场估算
  • 全球市场：CAGR 计算
  • 调查假设
  • 次要信息列表
  • 主要信息列表
  • 目的
  • 缩写列表

第 2 章执行摘要

  • 市场概况
  • 片段快照
  • 竞争格局快照

第 3 章市场变量、趋势和范围

  • 最小残留病检测市场谱系展望
    • 母公司市场展望
      • 细胞健康筛查市场展望
      • 体外诊断市场前景
  • 描绘渗透率和增长前景
  • 市场驱动因素分析
    • 癌症患病率增加
    • 增加对 MRD 测试的投资
    • 增加研究投资
  • 市场製约因素分析
    • 与 MRD 检查相关的高成本
    • 与 MRD 测试相关的复杂监管框架
  • SWOT 分析，按因素（政治和法律、经济、技术）
  • 波特的五力分析
  • 监管框架

第 4 章最小残留疾病检测市场-细分分析，按技术，2018-2030 年（百万美元）

  • 定义和范围
  • 最小残留病检测市场：技术波动分析
    • 流式细胞仪
    • 聚合□炼式反应 (PCR)
    • 下一代测序 (Ngs)
    • 其他

第 5 章最小残留疾病检测市场 - 细分分析，按癌症类型，2018-2030（百万美元）

  • 微小残留病检测市场：癌症类型的变异分析
    • 血液系统恶性肿瘤
    • 实体瘤

第 6 章最小残留疾病检测市场 - 细分分析，按业务划分，2018-2030 年（百万美元）

  • 定义和范围
  • 微小残留病检测市场：业务波动分析
    • 医院和专科诊所
    • 诊断实验室
    • 学术研究机构
    • 其他

第 7 章最小残留病检测市场-区域业务分析

  • 定义和范围
  • 2022 年和 2030 年区域市场份额分析
  • 区域市场仪表板
  • 区域市场概况
  • SWOT 分析，按因素（政治和法律、经济和技术）
    • 北美
    • 欧洲
    • 亚太地区
    • 拉丁美洲
    • 多边环境协定
  • 2022-2030 年市场规模、预测、趋势分析
  • 北美
    • 美国
      • 主要国家动态
      • 监管框架
      • 竞争场景
      • 最近的发展
      • 投资场景
    • 加拿大
      • 主要国家动态
      • 监管框架
      • 竞争场景
      • 最近的发展
      • 投资场景
  • 欧洲
    • 英国
      • 主要国家动态
      • 监管框架
      • 竞争场景
      • 最近的发展
      • 投资场景
    • 德国
      • 主要国家动态
      • 监管框架
      • 竞争场景
      • 最近的发展
      • 投资场景
    • 西班牙
      • 主要国家动态
      • 监管框架
      • 竞争场景
      • 最近的发展
      • 投资场景
    • 法国
      • 主要国家动态
      • 监管框架
      • 竞争场景
      • 最近的发展
      • 投资场景
    • 意大利
      • 主要国家动态
      • 监管框架
      • 竞争场景
      • 最近的发展
      • 投资场景
    • 丹麦
      • 主要国家动态
      • 监管框架
      • 竞争场景
      • 最近的发展
      • 投资场景
    • 瑞典
      • 主要国家动态
      • 监管框架
      • 竞争场景
      • 最近的发展
      • 投资场景
    • 挪威
      • 主要国家动态
      • 监管框架
      • 竞争场景
      • 最近的发展
      • 投资场景
  • 亚太地区
    • 日本
      • 主要国家动态
      • 监管框架
      • 竞争场景
      • 最近的发展
      • 投资场景
    • 中国
      • 主要国家动态
      • 监管框架
      • 竞争场景
      • 最近的发展
      • 投资场景
    • 印度
      • 主要国家动态
      • 监管框架
      • 竞争场景
      • 最近的发展
      • 投资场景
    • 韩国
      • 主要国家动态
      • 监管框架
      • 竞争场景
      • 最近的发展
      • 投资场景
    • 泰国
      • 主要国家动态
      • 监管框架
      • 竞争场景
      • 最近的发展
      • 投资场景
    • 澳大利亚
      • 主要国家动态
      • 监管框架
      • 竞争场景
      • 最近的发展
      • 投资场景
  • 拉丁美洲
    • 巴西
      • 主要国家动态
      • 监管框架
      • 竞争场景
      • 最近的发展
      • 投资场景
    • 墨西哥
      • 主要国家动态
      • 监管框架
      • 竞争场景
      • 最近的发展
      • 投资场景
    • 阿根廷
      • 主要国家动态
      • 监管框架
      • 竞争场景
      • 最近的发展
      • 投资场景
  • 多边环境协定
    • 南非
      • 主要国家动态
      • 监管框架
      • 竞争场景
      • 最近的发展
      • 投资场景
    • 沙特阿拉伯
      • 主要国家动态
      • 监管框架
      • 竞争场景
      • 最近的发展
      • 投资场景
    • 阿拉伯联合酋长国
      • 主要国家动态
      • 监管框架
      • 竞争场景
      • 最近的发展
      • 投资场景
    • 科威特
      • 主要国家动力学
      • 监管框架
      • 竞争场景
      • 最近的发展
      • 投资场景

第 8 章最小残留病检测市场-竞争分析

  • 公司/竞争对手分类（主要创新者、市场领导者、初创企业）
  • 战略框架
  • 市场参与分类
  • 主要市场进入者的近期趋势和影响分析
  • 公司定位分析
  • 分销商名单
    • 主要客户
    • 上市公司
    • 私人公司

第九章公司简介

  • 公司简介
    • EXACT SCIENCES CORPORATION,
      • 公司简介
      • 财务业绩
      • 产品基准
      • 战略举措
    • GRAIL, LLC
      • 公司简介
      • 财务业绩
      • 产品基准
      • 战略举措
    • VERACYTE, INC.
      • 公司简介
      • 财务业绩
      • 产品基准
      • 战略举措
    • NATERA, INC.
      • 公司简介
      • 财务业绩
      • 产品基准
      • 战略举措
    • GUARDANT HEALTH
      • 公司简介
      • 财务业绩
      • 产品基准
      • 战略举措
    • F. HOFFMANN-LA ROCHE LTD
      • 公司简介
      • 财务业绩
      • 产品基准
      • 战略举措
    • FOUNDATION MEDICINE, INC.
      • 公司简介
      • 财务业绩
      • 产品基准
      • 战略举措
    • QIAGEN
      • 公司简介
      • 财务业绩
      • 产品基准
      • 战略举措
    • MDXHEALTH
      • 公司简介
      • 财务业绩
      • 产品基准
      • 战略举措
    • BIO-TECHNE.
      • 公司简介
      • 财务业绩
      • 产品基准
      • 战略举措
Product Code: GVR-4-68040-016-3

Minimal Residue Disease Testing Market Growth & Trends:

The global minimal residual disease testing market size is expected to reach USD 4.50 billion by 2030, at a CAGR of 11.45% from 2023 to 2030, according to a new report by Grand View Research, Inc. The adoption of MRD testing as a novel diagnostic and prognostic assay facilitates robust moderation of treatment regimes to treat all kinds of hematological malignancies. Measurement of therapeutic outcomes is critical for the successful adoption of a given cancer therapeutic regime.

MRD generates important molecular information to better understand the cancer conditions and ultimately work towards leveraging treatment outcomes. Therefore, MRD testing is increasingly used as an end-point analysis step in numerous clinical trial studies for oncology-based research and also effectively records the variations in outcomes due to individual genetic characteristics. For instance, in November 2020, Adaptive Biotechnologies Corporation, entered into a collaboration with GlaxoSmithKline plc., to use its clonoSEQ assay for the assessment of residual cancer cells after treatment with GSK's hematology therapeutics.

Surgical removal of tumors with other associative therapies does not essentially mean, that the cancerous cells are removed completely. Traces of cancer can remain in the body parts and bloodstream. The diagnosis of such residual cells is crucial for deciding upon the need for further rounds of chemotherapy and radiation. Researchers are devising non-invasive tests to effectively detect MRD. For instance, in February 2022, a blood test from C2i Genomics quantified the residual cancer cells after surgical oncology procedures. The C2inform test also achieved the CE mark clearance and is offered as a 'software-as-a-medical-device' MRD test in Europe.

Cancer therapeutics are effectively moderated to avoid a residue of tumorous cells using the relevant clinical evidence and are also personalized based on specific progression profiles in an individual. Numerous research studies are driving the need for consideration of individual genetic characteristics for effective treatment. For instance, in October 2022, Adaptive Biotechnologies Corporation partnered with Epic for increasing access to MRD monitoring in blood cancers. Moreover, in February 2021, Natera Inc., collaborated with Personalis Inc., to understand the outcomes of personalized cancer care by integrating the NeXT tumor profiling (by Personalis) and the personalized ctDNA platform Signatera's diagnostic products (by Natera, Inc.,) for effectively designing the treatment monitoring regime and assessment of MRD.

Minimal Residue Disease Testing Market Report Highlights:

  • The flow cytometry segment held a dominant share in the minimal residual disease testing market in 2022 owing to the high sensitivity and wide applicability of MRD testing
  • The hematological malignancy segment is projected to grow at the fastest rate over the forecast period owing to the increasing prevalence of hematological malignancy
  • The hospitals and specialty clinics segment is the highest revenue-generating segment in 2022 owing to the availability of advanced diagnostic devices and skilled professionals in hospitals and specialty clinics
  • North America dominated the minimal residual disease testing market in 2022, which is attributed to the growing prevalence of hematological malignancies in the region aided by a well-developed reimbursement landscape

Table of Contents

Chapter 1 Methodology and Scope

  • 1.1 Market Segmentation
    • 1.1.1 Estimates And Forecast Timeline
  • 1.2 Research Methodology
  • 1.3 Information Procurement
    • 1.3.1 Purchased Database
    • 1.3.2 Secondary Sources
    • 1.3.3 Primary Research
    • 1.3.4 Details Of Primary Research
  • 1.4 Information Or Data Analysis
    • 1.4.1 Data Analysis Models
  • 1.5 Market Formulation & Validation
  • 1.6 Model Details
    • 1.6.1 Commodity Flow Analysis
      • 1.6.1.1 Approach 1: Commodity Flow Approach
      • 1.6.1.2 Approach 2: Country-Wise Market Estimation Using Bottom-Up Approach
  • 1.7 Global Market: Cagr Calculation
  • 1.8 Research Assumptions
  • 1.9 List Of Secondary Sources
  • 1.10 List Of Primary Sources
  • 1.11 Objectives
    • 1.11.1 Objective 1:
    • 1.11.2 Objective 2:
  • 1.12 List Of Abbreviations

Chapter 2 Executive Summary

  • 2.1 Market Snapshot
  • 2.2 Segment Snapshot
  • 2.3 Competitive Landscape Snapshot

Chapter 3 Market Variables, Trends & Scope

  • 3.1 Minimal Residual Disease Testing Market Lineage Outlook
    • 3.1.1 Parent Market Outlook
      • 3.1.1.1 Cellular Health Screening Market Outlook
      • 3.1.1.2 In Vitro Diagnostics Market Outlook
  • 3.2 Penetration And Growth Prospect Mapping
  • 3.3 Market Driver Analysis
    • 3.3.1 Increasing Prevalence Of Cancer
    • 3.3.2 Growing Investments In Mrd Testing
    • 3.3.3 Growing Investment For Research
  • 3.4 Market Restraint Analysis
    • 3.4.1 High-Cost Associated With Mrd Testing
    • 3.4.2 Complex Regulatory Framework Associated With Mrd Testing
  • 3.5 Swot Analysis, By Factor (Political & Legal, Economic, And Technological)
  • 3.6 Porter's Five Forces Analysis
  • 3.7 Regulatory Framework

Chapter 4 Minimal Residual Disease Testing Market - Segment Analysis, By Technology, 2018 - 2030 (USD Million)

  • 4.1 Definition And Scope
  • 4.2 Minimal Residual Disease Testing Market: Technology Movement Analysis
    • 4.2.1 Flow Cytometry
      • 4.2.1.1 Flow Cytometry Market Estimates And Forecast, 2018 - 2030 (USD Million)
    • 4.2.2 Polymerase Chain Reaction (Pcr)
      • 4.2.2.1 Polymerase Chain Reaction (Pcr) Market Estimates And Forecast, 2018 - 2030 (USD Million)
    • 4.2.3 Next Generation Sequencing (Ngs)
      • 4.2.3.1 Next Generation Sequencing Market Estimates And Forecast, 2018 - 2030 (USD Million)
    • 4.2.4 Others
      • 4.2.4.1 Others Market Estimates And Forecast, 2018 - 2030 (USD Million)

Chapter 5 Minimal Residual Disease Testing Market - Segment Analysis, By Cancer Type, 2018 - 2030 (USD Million)

  • 5.1 Minimal Residual Disease Testing Market: Cancer Type Movement Analysis
    • 5.1.1 Hematological Malignancy
      • 5.1.1.1 Hematological Malignancy Market Estimates And Forecast, 2018 - 2030 (USD Million)
    • 5.1.2 Solid Tumors
      • 5.1.2.1 Solid Tumors Market Estimates And Forecast, 2018 - 2030 (USD Million)

Chapter 6 Minimal Residual Disease Testing Market - Segment Analysis, By Business, 2018 - 2030 (USD Million)

  • 6.1 Definition And Scope
  • 6.2 Minimal Residual Disease Testing Market: Business Movement Analysis
    • 6.2.1 Hospitals And Speciality Clinics
      • 6.2.1.1 Hospitals And Speciality Clinics Market Estimates And Forecast, 2018 - 2030 (USD Million)
    • 6.2.2 Diagnostic Laboratories
      • 6.2.2.1 Diagnostic Laboratories Market Estimates And Forecast, 2018 - 2030 (USD Million)
    • 6.2.3 Academic And Research Institutes
      • 6.2.3.1 Research Institutes Market Estimates And Forecast, 2018 - 2030 (USD Million)
    • 6.2.4 Others
      • 6.2.4.1 Others Market Estimates And Forecast, 2018 - 2030 (USD Million)

Chapter 7 Minimal Residual Disease Testing Market - Regional Business Analysis

  • 7.1 Definition & Scope
  • 7.2 Regional Market Share Analysis, 2022 & 2030
  • 7.3 Regional Market Dashboard
  • 7.4 Regional Market Snapshot
  • 7.5 Swot Analysis, By Factor (Political & Legal, Economic And Technological)
    • 7.5.1 North America
    • 7.5.2 Europe
    • 7.5.3 Asia Pacific
    • 7.5.4 Latin America
    • 7.5.5 MEA
  • 7.6 Market Size, & Forecasts, Trend Analysis, 2022 to 2030
  • 7.7 North America
    • 7.7.1 North America Market Estimates And Forecast, 2018 - 2030 (USD MILLION)
    • 7.7.2 U.S.
      • 7.7.2.1 U.S. Minimal Residual Disease Testing Market, 2018 - 2030 (USD Million)
      • 7.7.2.2 Key country Dynamics
      • 7.7.2.3 Regulatory Framework
      • 7.7.2.4 Competitive Scenario
      • 7.7.2.5 Recent Developments
      • 7.7.2.6 Investments Scenario
    • 7.7.3 Canada
      • 7.7.3.1 Canada Minimal Residual Disease Testing Market, 2018 - 2030 (USD Million)
      • 7.7.3.2 Key country Dynamics
      • 7.7.3.3 Regulatory Framework
      • 7.7.3.4 Competitive Scenario
      • 7.7.3.5 Recent Developments
      • 7.7.3.6 Investments Scenario
  • 7.8 Europe
    • 7.8.1 Europe Minimal Residual Disease Testing Market, 2018 - 2030 (USD Million)
    • 7.8.2 UK
      • 7.8.2.1 UK Minimal Residual Disease Testing Market, 2018 - 2030 (USD Million)
      • 7.8.2.2 Key country Dynamics
      • 7.8.2.3 Regulatory Framework
      • 7.8.2.4 Competitive Scenario
      • 7.8.2.5 Recent Developments
      • 7.8.2.6 Investments Scenario
    • 7.8.3 Germany
      • 7.8.3.1 Germany Minimal Residual Disease Testing Market, 2018 - 2030 (USD Million)
      • 7.8.3.2 Key country Dynamics
      • 7.8.3.3 Regulatory Framework
      • 7.8.3.4 Competitive Scenario
      • 7.8.3.5 Recent Developments
      • 7.8.3.6 Investments Scenario
    • 7.8.4 Spain
      • 7.8.4.1 Spain Minimal Residual Disease Testing Market, 2018 - 2030 (USD Million)
      • 7.8.4.2 Key country Dynamics
      • 7.8.4.3 Regulatory Framework
      • 7.8.4.4 Competitive Scenario
      • 7.8.4.5 Recent Developments
      • 7.8.4.6 Investments Scenario
    • 7.8.5 France
      • 7.8.5.1 France Minimal Residual Disease Testing Market, 2018 - 2030 (USD Million)
      • 7.8.5.2 Key country Dynamics
      • 7.8.5.3 Regulatory Framework
      • 7.8.5.4 Competitive Scenario
      • 7.8.5.5 Recent Developments
      • 7.8.5.6 Investments Scenario
    • 7.8.6 Italy
      • 7.8.6.1 Italy Minimal Residual Disease Testing Market, 2018 - 2030 (USD Million)
      • 7.8.6.2 Key country Dynamics
      • 7.8.6.3 Regulatory Framework
      • 7.8.6.4 Competitive Scenario
      • 7.8.6.5 Recent Developments
      • 7.8.6.6 Investments Scenario
    • 7.8.7 Denmark
      • 7.8.7.1 Denmark Minimal Residual Disease Testing Market, 2018 - 2030 (USD Million)
      • 7.8.7.2 Key country Dynamics
      • 7.8.7.3 Regulatory Framework
      • 7.8.7.4 Competitive Scenario
      • 7.8.7.5 Recent Developments
      • 7.8.7.6 Investments Scenario
    • 7.8.8 Sweden
      • 7.8.8.1 Sweden Minimal Residual Disease Testing Market, 2018 - 2030 (USD Million)
      • 7.8.8.2 Key country Dynamics
      • 7.8.8.3 Regulatory Framework
      • 7.8.8.4 Competitive Scenario
      • 7.8.8.5 Recent Developments
      • 7.8.8.6 Investments Scenario
    • 7.8.9 Norway
      • 7.8.9.1 Norway Minimal Residual Disease Testing Market, 2018 - 2030 (USD Million)
      • 7.8.9.2 Key country Dynamics
      • 7.8.9.3 Regulatory Framework
      • 7.8.9.4 Competitive Scenario
      • 7.8.9.5 Recent Developments
      • 7.8.9.6 Investments Scenario
  • 7.9 Asia Pacific
    • 7.9.1 Asia-Pacific Minimal Residual Disease Testing Market, 2018 - 2030 (USD Million)
    • 7.9.2 Japan
      • 7.9.2.1 Japan Minimal Residual Disease Testing Market, 2018 - 2030 (USD Million)
      • 7.9.2.2 Key country Dynamics
      • 7.9.2.3 Regulatory Framework
      • 7.9.2.4 Competitive Scenario
      • 7.9.2.5 Recent Developments
      • 7.9.2.6 Investments Scenario
    • 7.9.3 China
      • 7.9.3.1 China Minimal Residual Disease Testing Market, 2018 - 2030 (USD Million)
      • 7.9.3.2 Key country Dynamics
      • 7.9.3.3 Regulatory Framework
      • 7.9.3.4 Competitive Scenario
      • 7.9.3.5 Recent Developments
      • 7.9.3.6 Investments Scenario
    • 7.9.4 India
      • 7.9.4.1 India Minimal Residual Disease Testing Market, 2018 - 2030 (USD Million)
      • 7.9.4.2 Key country Dynamics
      • 7.9.4.3 Regulatory Framework
      • 7.9.4.4 Competitive Scenario
      • 7.9.4.5 Recent Developments
      • 7.9.4.6 Investments Scenario
    • 7.9.5 South Korea
      • 7.9.5.1 South Korea Minimal Residual Disease Testing Market, 2018 - 2030 (USD Million)
      • 7.9.5.2 Key country Dynamics
      • 7.9.5.3 Regulatory Framework
      • 7.9.5.4 Competitive Scenario
      • 7.9.5.5 Recent Developments
      • 7.9.5.6 Investments Scenario
    • 7.9.6 Thailand
      • 7.9.6.1 Thailand Minimal Residual Disease Testing Market, 2018 - 2030 (USD Million)
      • 7.9.6.2 Key country Dynamics
      • 7.9.6.3 Regulatory Framework
      • 7.9.6.4 Competitive Scenario
      • 7.9.6.5 Recent Developments
      • 7.9.6.6 Investments Scenario
    • 7.9.7 Australia
      • 7.9.7.1 Australia Minimal Residual Disease Testing Market, 2018 - 2030 (USD Million)
      • 7.9.7.2 Key country Dynamics
      • 7.9.7.3 Regulatory Framework
      • 7.9.7.4 Competitive Scenario
      • 7.9.7.5 Recent Developments
      • 7.9.7.6 Investments Scenario
  • 7.10 Latin America
    • 7.10.1 Latin America Minimal Residual Disease Testing Market, 2018 - 2030 (USD Million)
    • 7.10.2 Brazil
      • 7.10.2.1 Brazil Minimal Residual Disease Testing Market, 2018 - 2030 (USD Million)
      • 7.10.2.2 Key country Dynamics
      • 7.10.2.3 Regulatory Framework
      • 7.10.2.4 Competitive Scenario
      • 7.10.2.5 Recent Developments
      • 7.10.2.6 Investments Scenario
    • 7.10.3 Mexico
      • 7.10.3.1 Mexico Minimal Residual Disease Testing Market, 2018 - 2030 (USD Million)
      • 7.10.3.2 Key country Dynamics
      • 7.10.3.3 Regulatory Framework
      • 7.10.3.4 Competitive Scenario
      • 7.10.3.5 Recent Developments
      • 7.10.3.6 Investments Scenario
    • 7.10.4 Argentina
      • 7.10.4.1 Argentina Minimal Residual Disease Testing Market, 2018 - 2030 (USD Million)
      • 7.10.4.2 Key country Dynamics
      • 7.10.4.3 Regulatory Framework
      • 7.10.4.4 Competitive Scenario
      • 7.10.4.5 Recent Developments
      • 7.10.4.6 Investments Scenario
  • 7.11 MEA
    • 7.11.1 MEA Minimal Residual Disease Testing Market, 2018 - 2030 (USD Million)
    • 7.11.2 South Africa
      • 7.11.2.1 South Africa Minimal Residual Disease Testing Market, 2018 - 2030 (USD Million)
      • 7.11.2.2 Key country Dynamics
      • 7.11.2.3 Regulatory Framework
      • 7.11.2.4 Competitive Scenario
      • 7.11.2.5 Recent Developments
      • 7.11.2.6 Investments Scenario
    • 7.11.3 Saudi Arabia
      • 7.11.3.1 Saudi Arabia Minimal Residual Disease Testing Market, 2018 - 2030 (USD Million)
      • 7.11.3.2 Key country Dynamics
      • 7.11.3.3 Regulatory Framework
      • 7.11.3.4 Competitive Scenario
      • 7.11.3.5 Recent Developments
      • 7.11.3.6 Investments Scenario
    • 7.11.4 UAE
      • 7.11.4.1 UAE Minimal Residual Disease Testing Market, 2018 - 2030 (USD Million)
      • 7.11.4.2 Key country Dynamics
      • 7.11.4.3 Regulatory Framework
      • 7.11.4.4 Competitive Scenario
      • 7.11.4.5 Recent Developments
      • 7.11.4.6 Investments Scenario
    • 7.11.5 Kuwait
      • 7.11.5.1 Kuwait Minimal Residual Disease Testing Market, 2018 - 2030 (USD Million)
      • 7.11.5.2 Key country Dynamics
      • 7.11.5.3 Regulatory Framework
      • 7.11.5.4 Competitive Scenario
      • 7.11.5.5 Recent Developments
      • 7.11.5.6 Investments Scenario

Chapter 8 Minimal Residual Disease Testing Market - Competitive Analysis

  • 8.1 Company/Competition Categorization (Key Innovators, Market leaders, Emerging Players)
  • 8.2 Strategy Framework
  • 8.3 Market Participation Categorization
  • 8.4 Recent Developments & Impact Analysis, by Key Market Participants
  • 8.5 Company Position Analysis
  • 8.6 List of Distributors
    • 8.6.1 Key Customers
    • 8.6.2 Public Companies
    • 8.6.3 Private Companies

Chapter 9 Company Profiles

  • 9.1 Company Profiles
    • 9.1.1 EXACT SCIENCES CORPORATION,
      • 9.1.1.1 Company Overview
      • 9.1.1.2 Financial Performance
      • 9.1.1.3 Product Benchmarking
      • 9.1.1.4 Strategic Initiatives
    • 9.1.2 GRAIL, LLC
      • 9.1.2.1 Company Overview
      • 9.1.2.2 Financial performance
      • 9.1.2.3 Product Benchmarking
      • 9.1.2.4 Strategic Initiatives
    • 9.1.3 VERACYTE, INC.
      • 9.1.3.1 Company Overview
      • 9.1.3.2 Financial performance
      • 9.1.3.3 Product Benchmarking
      • 9.1.3.4 Strategic Initiatives
    • 9.1.4 NATERA, INC.
      • 9.1.4.1 Company Overview
      • 9.1.4.2 Financial performance
      • 9.1.4.3 Product Benchmarking
      • 9.1.4.4 Strategic Initiatives
    • 9.1.5 GUARDANT HEALTH
      • 9.1.5.1 Company Overview
      • 9.1.5.2 Financial performance
      • 9.1.5.3 Product Benchmarking
      • 9.1.5.4 Strategic Initiatives
    • 9.1.6 F. HOFFMANN-LA ROCHE LTD
      • 9.1.6.1 Company Overview
      • 9.1.6.2 Financial performance
      • 9.1.6.3 Product Benchmarking
      • 9.1.6.4 Strategic Initiatives
    • 9.1.7 FOUNDATION MEDICINE, INC.
      • 9.1.7.1 Company Overview
      • 9.1.7.2 Financial performance
      • 9.1.7.3 Product Benchmarking
      • 9.1.7.4 Strategic Initiatives
    • 9.1.8 QIAGEN
      • 9.1.8.1 Company Overview
      • 9.1.8.2 Financial performance
      • 9.1.8.3 Product Benchmarking
      • 9.1.8.4 Strategic Initiatives
    • 9.1.9 MDXHEALTH
      • 9.1.9.1 Company Overview
      • 9.1.9.2 Financial performance
      • 9.1.9.3 Product Benchmarking
      • 9.1.9.4 Strategic Initiatives
    • 9.1.10 BIO-TECHNE.
      • 9.1.10.1 Company Overview
      • 9.1.10.2 Financial performance
      • 9.1.10.3 Product Benchmarking
      • 9.1.10.4 Strategic Initiatives

List of Tables

  • Table 1 List of Secondary Sources
  • Table 2 List of Abbreviations
  • Table 3 Regulatory Framework
  • Table 4 Global Minimal Residual Disease Testing Market, By Region, 2018 - 2030 (USD Million)
  • Table 5 Global Minimal Residual Disease Testing Market, By Technology, 2018 - 2030 (USD Million)
  • Table 6 Global Minimal Residual Disease Testing Market, By Cancer Type, 2018 - 2030 (USD Million)
  • Table 7 Global Minimal Residual Disease Testing Market, By End-Use, 2018 - 2030 (USD Million)
  • Table 8 North America Minimal Residual Disease Testing Market, By Country, 2018 - 2030 (USD Million)
  • Table 9 North America Minimal Residual Disease Testing Market, By Technology, 2018 - 2030 (USD Million)
  • Table 10 North America Minimal Residual Disease Testing Market, By Cancer Type, 2018 - 2030 (USD Million)
  • Table 11 North America Minimal Residual Disease Testing Market, By End-Use, 2018 - 2030 (USD Million)
  • Table 12 U.S. Minimal Residual Disease Testing Market, By Technology, 2018 - 2030 (USD Million)
  • Table 13 U.S. Minimal Residual Disease Testing Market, By Cancer Type, 2018 - 2030 (USD Million)
  • Table 14 U.S. Minimal Residual Disease Testing Market, By End-Use, 2018 - 2030 (USD Million)
  • Table 15 Canada Minimal Residual Disease Testing Market, By Technology, 2018 - 2030 (USD Million)
  • Table 16 Canada Minimal Residual Disease Testing Market, By Cancer Type, 2018 - 2030 (USD Million)
  • Table 17 Canada Minimal Residual Disease Testing Market, By End-Use, 2018 - 2030 (USD Million)
  • Table 18 Europe Minimal Residual Disease Testing Market, By Country, 2018 - 2030 (USD Million)
  • Table 19 Europe Minimal Residual Disease Testing Market, By Technology, 2018 - 2030 (USD Million)
  • Table 20 Europe Minimal Residual Disease Testing Market, By Cancer Type, 2018 - 2030 (USD Million)
  • Table 21 Europe Minimal Residual Disease Testing Market, By End-Use, 2018 - 2030 (USD Million)
  • Table 22 UK Minimal Residual Disease Testing Market, By Technology, 2018 - 2030 (USD Million)
  • Table 23 UK Minimal Residual Disease Testing Market, By Cancer Type, 2018 - 2030 (USD Million)
  • Table 24 UK Minimal Residual Disease Testing Market, By End-Use, 2018 - 2030 (USD Million)
  • Table 25 Germany Minimal Residual Disease Testing Market, By Technology, 2018 - 2030 (USD Million)
  • Table 26 Germany Minimal Residual Disease Testing Market, By Cancer Type, 2018 - 2030 (USD Million)
  • Table 27 Germany Minimal Residual Disease Testing Market, By End-Use, 2018 - 2030 (USD Million)
  • Table 28 France Minimal Residual Disease Testing Market, By Technology, 2018 - 2030 (USD Million)
  • Table 29 France Minimal Residual Disease Testing Market, By Cancer Type, 2018 - 2030 (USD Million)
  • Table 30 France Minimal Residual Disease Testing Market, By End-Use, 2018 - 2030 (USD Million)
  • Table 31 Spain Minimal Residual Disease Testing Market, By Technology, 2018 - 2030 (USD Million)
  • Table 32 Spain Minimal Residual Disease Testing Market, By Cancer Type, 2018 - 2030 (USD Million)
  • Table 33 Spain Minimal Residual Disease Testing Market, By End-Use, 2018 - 2030 (USD Million)
  • Table 34 Italy Minimal Residual Disease Testing Market, By Technology, 2018 - 2030 (USD Million)
  • Table 35 Italy Minimal Residual Disease Testing Market, By Cancer Type, 2018 - 2030 (USD Million)
  • Table 36 Italy Minimal Residual Disease Testing Market, By End-Use, 2018 - 2030 (USD Million)
  • Table 37 Denmark Minimal Residual Disease Testing Market, By Technology, 2018 - 2030 (USD Million)
  • Table 38 Denmark Minimal Residual Disease Testing Market, By Cancer Type, 2018 - 2030 (USD Million)
  • Table 39 Denmark Minimal Residual Disease Testing Market, By End-Use, 2018 - 2030 (USD Million)
  • Table 40 Sweden Minimal Residual Disease Testing Market, By Technology, 2018 - 2030 (USD Million)
  • Table 41 Sweden Minimal Residual Disease Testing Market, By Cancer Type, 2018 - 2030 (USD Million)
  • Table 42 Sweden Minimal Residual Disease Testing Market, By End-Use, 2018 - 2030 (USD Million)
  • Table 43 Norway Minimal Residual Disease Testing Market, By Technology, 2018 - 2030 (USD Million)
  • Table 44 Norway Minimal Residual Disease Testing Market, By Cancer Type, 2018 - 2030 (USD Million)
  • Table 45 Norway Minimal Residual Disease Testing Market, By End-Use, 2018 - 2030 (USD Million)
  • Table 46 Asia Pacific Minimal Residual Disease Testing Market, By Country, 2018 - 2030 (USD Million)
  • Table 47 Asia Pacific Minimal Residual Disease Testing Market, By Technology, 2018 - 2030 (USD Million)
  • Table 48 Asia Pacific Minimal Residual Disease Testing Market, By Cancer Type, 2018 - 2030 (USD Million)
  • Table 49 Asia Pacific Minimal Residual Disease Testing Market, By End-Use, 2018 - 2030 (USD Million)
  • Table 50 Japan Minimal Residual Disease Testing Market, By Technology, 2018 - 2030 (USD Million)
  • Table 51 Japan Minimal Residual Disease Testing Market, By Cancer Type, 2018 - 2030 (USD Million)
  • Table 52 Japan Minimal Residual Disease Testing Market, By End-Use, 2018 - 2030 (USD Million)
  • Table 53 China Minimal Residual Disease Testing Market, By Technology, 2018 - 2030 (USD Million)
  • Table 54 China Minimal Residual Disease Testing Market, By Cancer Type, 2018 - 2030 (USD Million)
  • Table 55 China Minimal Residual Disease Testing Market, By End-Use, 2018 - 2030 (USD Million)
  • Table 56 Australia Minimal Residual Disease Testing Market, By Technology, 2018 - 2030 (USD Million)
  • Table 57 Australia Minimal Residual Disease Testing Market, By Cancer Type, 2018 - 2030 (USD Million)
  • Table 58 Australia Minimal Residual Disease Testing Market, By End-Use, 2018 - 2030 (USD Million)
  • Table 59 Thailand Minimal Residual Disease Testing Market, By Technology, 2018 - 2030 (USD Million)
  • Table 60 Thailand Minimal Residual Disease Testing Market, By Cancer Type, 2018 - 2030 (USD Million)
  • Table 61 Thailand Minimal Residual Disease Testing Market, By End-Use, 2018 - 2030 (USD Million)
  • Table 62 India Minimal Residual Disease Testing Market, By Technology, 2018 - 2030 (USD Million)
  • Table 63 India Minimal Residual Disease Testing Market, By Cancer Type, 2018 - 2030 (USD Million)
  • Table 64 India Minimal Residual Disease Testing Market, By End-Use, 2018 - 2030 (USD Million)
  • Table 65 South Korea Minimal Residual Disease Testing Market, By Technology, 2018 - 2030 (USD Million)
  • Table 66 South Korea Minimal Residual Disease Testing Market, By Cancer Type, 2018 - 2030 (USD Million)
  • Table 67 South Korea Minimal Residual Disease Testing Market, By End-Use, 2018 - 2030 (USD Million)
  • Table 68 Latin America Minimal Residual Disease Testing Market, By Country, 2018 - 2030 (USD Million)
  • Table 69 Latin America Minimal Residual Disease Testing Market, By Technology, 2018 - 2030 (USD Million)
  • Table 70 Latin America Minimal Residual Disease Testing Market, By Cancer Type, 2018 - 2030 (USD Million)
  • Table 71 Latin America Minimal Residual Disease Testing Market, By End-Use, 2018 - 2030 (USD Million)
  • Table 72 Mexico Minimal Residual Disease Testing Market, By Technology, 2018 - 2030 (USD Million)
  • Table 73 Mexico Minimal Residual Disease Testing Market, By Cancer Type, 2018 - 2030 (USD Million)
  • Table 74 Mexico Minimal Residual Disease Testing Market, By End-Use, 2018 - 2030 (USD Million)
  • Table 75 Brazil Minimal Residual Disease Testing Market, By Technology, 2018 - 2030 (USD Million)
  • Table 76 Brazil Minimal Residual Disease Testing Market, By Cancer Type, 2018 - 2030 (USD Million)
  • Table 77 Brazil Minimal Residual Disease Testing Market, By End-Use, 2018 - 2030 (USD Million)
  • Table 78 Argentina Minimal Residual Disease Testing Market, By Technology, 2018 - 2030 (USD Million)
  • Table 79 Argentina Minimal Residual Disease Testing Market, By Cancer Type, 2018 - 2030 (USD Million)
  • Table 80 Argentina Minimal Residual Disease Testing Market, By End-Use, 2018 - 2030 (USD Million)
  • Table 81 MEA Minimal Residual Disease Testing Market, By Country, 2018 - 2030 (USD Million)
  • Table 82 MEA Minimal Residual Disease Testing Market, By Technology, 2018 - 2030 (USD Million)
  • Table 83 MEA Minimal Residual Disease Testing Market, By Cancer Type, 2018 - 2030 (USD Million)
  • Table 84 MEA Minimal Residual Disease Testing Market, By End-Use, 2018 - 2030 (USD Million)
  • Table 85 South Africa Minimal Residual Disease Testing Market, By Technology, 2018 - 2030 (USD Million)
  • Table 86 South Africa Minimal Residual Disease Testing Market, By Cancer Type, 2018 - 2030 (USD Million)
  • Table 87 South Africa Minimal Residual Disease Testing Market, By End-Use, 2018 - 2030 (USD Million)
  • Table 88 Saudi Arabia Minimal Residual Disease Testing Market, By Technology, 2018 - 2030 (USD Million)
  • Table 89 Saudi Arabia Minimal Residual Disease Testing Market, By Cancer Type, 2018 - 2030 (USD Million)
  • Table 90 Saudi Arabia Minimal Residual Disease Testing Market, By End-Use, 2018 - 2030 (USD Million)
  • Table 91 UAE Minimal Residual Disease Testing Market, By Technology, 2018 - 2030 (USD Million)
  • Table 92 UAE Minimal Residual Disease Testing Market, By Cancer Type, 2018 - 2030 (USD Million)
  • Table 93 UAE Minimal Residual Disease Testing Market, By End-Use, 2018 - 2030 (USD Million)
  • Table 94 Kuwait Minimal Residual Disease Testing Market, By Technology, 2018 - 2030 (USD Million)
  • Table 95 Kuwait Minimal Residual Disease Testing Market, By Cancer Type, 2018 - 2030 (USD Million)
  • Table 96 Kuwait Minimal Residual Disease Testing Market, By End-Use, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market Research Process
  • Fig. 2 Information Procurement
  • Fig. 3 Primary Research Pattern
  • Fig. 4 Market Research Approaches
  • Fig. 5 Value Chain-Based Sizing & Forecasting
  • Fig. 6 Market Formulation & Validation
  • Fig. 7 Gastroesophageal Reflux Disease Therapeutics Market Segmentation
  • Fig. 8 Market Driver Relevance Analysis (Current & Future Impact)
  • Fig. 9 Market Restraint Relevance Analysis (Current & Future Impact)
  • Fig. 10 Market Challenge Relevance Analysis (Current & Future Impact)
  • Fig. 11 Penetration & Growth Prospect Mapping
  • Fig. 12 SWOT Analysis, By Factor (Political & Legal, Economic and Technological)
  • Fig. 13 Porter's Five Forces Analysis
  • Fig. 14 Market Penetration & Growth Prospect Mapping
  • Fig. 15 Minimal residual disease testing market: Technology outlook and key takeaways
  • Fig. 16 Minimal residual disease testing market: Technology movement analysis & market share 2022 & 2030
  • Fig. 17 Flow cytometry market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 18 Polymerase chain reaction (PCR) market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 19 Next generation sequencing (NGS) market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 20 Others market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 21 Minimal residual disease testing market: Cancer type outlook and key takeaways
  • Fig. 22 Minimal residual disease testing market: Cancer type movement analysis & market share 2022 & 2030
  • Fig. 23 Haematological malignancy market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 24 Solid tumors market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 25 Minimal residual disease testing market: End-Use outlook and key takeaways
  • Fig. 26 Minimal residual disease testing market: End-Use movement analysis & market share 2022 & 2030
  • Fig. 27 Hospitals and specialty clinics market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 28 Diagnostic laboratories market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 29 Academic and research institutes market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 30 Others market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 31 Regional Marketplace: Key Takeaways
  • Fig. 32 Regional Outlook, 2022 & 2030
  • Fig. 33 Regional Market Dashboard
  • Fig. 34 Regional Market Place: Key Takeaways
  • Fig. 35 North America, SWOT Analysis
  • Fig. 36 Europe, SWOT Analysis
  • Fig. 37 Asia Pacific, SWOT Analysis
  • Fig. 38 Latin America, SWOT Analysis
  • Fig. 39 MEA, SWOT Analysis
  • Fig. 40 North America
  • Fig. 41 North America Market Estimates and Forecast, 2018 - 2030 (USD Million)
  • Fig. 42 U.S.
  • Fig. 43 U.S. Market Estimates and Forecast, 2018 - 2030 (USD Million)
  • Fig. 44 Canada
  • Fig. 45 Canada Market Estimates and Forecast, 2018 - 2030 (USD Million)
  • Fig. 46 Europe
  • Fig. 47 Europe Market Estimates and Forecast, 2018 - 2030 (USD Million)
  • Fig. 48 UK
  • Fig. 49 UK Market Estimates and Forecast, 2018 - 2030 (USD Million)
  • Fig. 50 Germany
  • Fig. 51 Germany Market Estimates and Forecast, 2018 - 2030 (USD Million)
  • Fig. 52 France
  • Fig. 53 France Market Estimates and Forecast, 2018 - 2030 (USD Million)
  • Fig. 54 Italy
  • Fig. 55 Italy Market Estimates and Forecast, 2018 - 2030 (USD Million)
  • Fig. 56 Spain
  • Fig. 57 Spain Market Estimates and Forecast, 2018 - 2030 (USD Million)
  • Fig. 58 Denmark
  • Fig. 59 Denmark Market Estimates and Forecast, 2018 - 2030 (USD Million)
  • Fig. 60 Sweden
  • Fig. 61 Sweden Market Estimates and Forecast, 2018 - 2030 (USD Million)
  • Fig. 62 Norway
  • Fig. 63 Norway Market Estimates and Forecast, 2018 - 2030 (USD Million)
  • Fig. 64 Asia Pacific
  • Fig. 65 Asia-Pacific Market Estimates and Forecast, 2018 - 2030 (USD Million)
  • Fig. 66 Japan
  • Fig. 67 Japan Market Estimates and Forecast, 2018 - 2030 (USD Million)
  • Fig. 68 China
  • Fig. 69 China Market Estimates and Forecast, 2018 - 2030 (USD Million)
  • Fig. 70 India
  • Fig. 71 India Market Estimates and Forecast, 2018 - 2030 (USD Million)
  • Fig. 72 Australia
  • Fig. 73 Australia Market Estimates and Forecast, 2018 - 2030 (USD Million)
  • Fig. 74 Thailand
  • Fig. 75 Thailand Market Estimates and Forecast, 2018 - 2030 (USD Million)
  • Fig. 76 South Korea
  • Fig. 77 South Korea Market Estimates and Forecast, 2018 - 2030 (USD Million)
  • Fig. 78 Latin America
  • Fig. 79 Latin America Market Estimates and Forecast, 2018 - 2030 (USD Million)
  • Fig. 80 Brazil
  • Fig. 81 Brazil Market Estimates and Forecast, 2018 - 2030 (USD Million)
  • Fig. 82 Mexico
  • Fig. 83 Mexico Market Estimates and Forecast, 2018 - 2030 (USD Million)
  • Fig. 84 Argentina
  • Fig. 85 Argentina Market Estimates and Forecast, 2018 - 2030 (USD Million)
  • Fig. 86 MEA
  • Fig. 87 MEA Market Estimates and Forecast, 2018 - 2030 (USD Million)
  • Fig. 88 South Africa
  • Fig. 89 South Africa Market Estimates and Forecast, 2018 - 2030 (USD Million)
  • Fig. 90 Saudi Arabia
  • Fig. 91 Saudi Arabia Market Estimates and Forecast, 2018 - 2030 (USD Million)
  • Fig. 92 UAE
  • Fig. 93 UAE Market Estimates and Forecast, 2018 - 2030 (USD Million)
  • Fig. 94 Kuwait
  • Fig. 95 Kuwait Market Estimates and Forecast, 2018 - 2030 (USD Million)
  • Fig. 96 Strategy Mapping